home > ict > autumn 2020 > modernisation movement
International Clinical Trials

Modernisation Movement

EPC: Has the process of modernising site operations slowed due to the pandemic?

Anna Argyris: COVID-19 halted a large number of trials. This slowed research, but actually accelerated modernisation efforts in site operations. As sites are now navigating new ways of working, technology has played an important role in allowing sites to reopen safely.

We're hearing from multiple sites that COVID-19 has been a catalysing event for them, especially those that did not previously have technology solutions in place. In some cases, the pandemic has given sites the business justification they needed to be able to accelerate their modernisation efforts. At the same time, sites have focused on reducing the burden on patients participating in clinical trials. Patients take a significant amount of time out of their lives to participate in research. For some patients, the burden of a trial can become too great and they may need to withdraw from a study or not complete important follow-up study visits. The future of clinical studies lies with helping sites and patients eliminate some of those burdens through technology.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Anna Argyris, Director of Site Solutions at Veeva Systems, has over 10 years of clinical research leadership experience and has worked at Mayo Clinic, Georgetown University, Houston Methodist, and UCSF. She led several technical projects involving CTMS, EHR, eTMF, and eRegulatory systems. Her research expertise includes study feasibility and logistics planning, finance and forecasting, programme development, coverage analysis, billing compliance, and business process design. Anna currently supports the strategy for Veeva’s research site solutions.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

First patient dosed in the CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host Disease Company discontinues the development of first-generation, autologous CAR T candidate CYAD-01 based on clinical futility observed to date from the Phase 1 THINK trial Preliminary data from CYCLE-1 trial evaluating next-generation autologous CYAD-02 in r/r AML / MDS patients showed encouraging clinical signals, including a high-risk MDS patient treated at dose level 3 who achieved an objective marrow complete response; dose level 3 cohort of the CYCLE-1 trial is ongoing Management to hold a conference call later today, December 7, at 1 p.m. CET/ 7 a.m. ET
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement